Viola Ghizzoni

621 total citations
27 papers, 303 citations indexed

About

Viola Ghizzoni is a scholar working on Reproductive Medicine, Oncology and Obstetrics and Gynecology. According to data from OpenAlex, Viola Ghizzoni has authored 27 papers receiving a total of 303 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Reproductive Medicine, 14 papers in Oncology and 13 papers in Obstetrics and Gynecology. Recurrent topics in Viola Ghizzoni's work include Ovarian cancer diagnosis and treatment (19 papers), Endometrial and Cervical Cancer Treatments (11 papers) and PARP inhibition in cancer therapy (11 papers). Viola Ghizzoni is often cited by papers focused on Ovarian cancer diagnosis and treatment (19 papers), Endometrial and Cervical Cancer Treatments (11 papers) and PARP inhibition in cancer therapy (11 papers). Viola Ghizzoni collaborates with scholars based in Italy, United States and Argentina. Viola Ghizzoni's co-authors include Giovanni Scambia, Vanda Salutari, Caterina Ricci, Domenica Lorusso, Elena Giudice, Lucia Musacchio, Floriana Camarda, Camilla Nero, Ivo Noci and Massimiliano Fambrini and has published in prestigious journals such as PLoS ONE, Annals of Oncology and BioMed Research International.

In The Last Decade

Viola Ghizzoni

24 papers receiving 298 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Viola Ghizzoni Italy	9	136	129	112	75	45	27	303
Luis Z. Blanco United States	11	86 0.6×	60 0.5×	165 1.5×	69 0.9×	63 1.4×	32	358
Konstantina Tatsi Greece	6	169 1.2×	120 0.9×	142 1.3×	65 0.9×	21 0.5×	6	329
Shujie Pang China	8	114 0.8×	64 0.5×	52 0.5×	89 1.2×	40 0.9×	22	282
Monica Ragnoli Italy	7	206 1.5×	165 1.3×	41 0.4×	60 0.8×	25 0.6×	9	296
Angèle L.M. Oei Netherlands	7	176 1.3×	44 0.3×	99 0.9×	75 1.0×	48 1.1×	16	368
Robertson Mackenzie Canada	6	233 1.7×	139 1.1×	52 0.5×	96 1.3×	23 0.5×	6	334
Gonzalo Giornelli Argentina	5	241 1.8×	254 2.0×	110 1.0×	84 1.1×	25 0.6×	8	421
Koji Nishino Japan	10	91 0.7×	49 0.4×	89 0.8×	113 1.5×	22 0.5×	20	259
Alejandra Wernicke Argentina	10	45 0.3×	63 0.5×	99 0.9×	59 0.8×	44 1.0×	33	236
Anna Dańska-Bidzińska Poland	11	190 1.4×	175 1.4×	79 0.7×	68 0.9×	20 0.4×	42	405

Countries citing papers authored by Viola Ghizzoni

Since Specialization

Citations

This map shows the geographic impact of Viola Ghizzoni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Viola Ghizzoni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Viola Ghizzoni more than expected).

Fields of papers citing papers by Viola Ghizzoni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Viola Ghizzoni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Viola Ghizzoni. The network helps show where Viola Ghizzoni may publish in the future.

Co-authorship network of co-authors of Viola Ghizzoni

This figure shows the co-authorship network connecting the top 25 collaborators of Viola Ghizzoni. A scholar is included among the top collaborators of Viola Ghizzoni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Viola Ghizzoni. Viola Ghizzoni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Musacchio, Lucia, Serena Maria Boccia, Cláudia Marchetti, et al.. (2023). Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors. International Journal of Gynecological Cancer. 33(6). 922–928. 1 indexed citations

Salutari, Vanda, Cláudia Marchetti, Viola Ghizzoni, et al.. (2023). #881 The NUVOLA TRIAL: neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel. A phase II open-label multi-centre study. A430.3–A431.

Agostinelli, Veronica, Lucia Musacchio, Floriana Camarda, et al.. (2023). Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data. Cancer Management and Research. Volume 15. 1063–1072. 6 indexed citations

Salutari, Vanda, Viola Ghizzoni, Elena Giudice, et al.. (2023). Genome tumor profiling in endometrial cancer and clinical relevance in endometrial cancer management: a retrospective single-center experience. International Journal of Gynecological Cancer. 33(4). 514–520. 2 indexed citations

Musacchio, Lucia, Vanda Salutari, Sandro Pignata, et al.. (2022). 2022-RA-1540-ESGO MITO 25.1: a randomized, molecular driven phase II trial of carboplatin-paclitaxel-bevacizumab vs carboplatin-paclitaxel-bevacizumab-rucaparib vs carboplatin-paclitaxel-rucaparib, selected according to HRD status, in patients with advanced (Stage III B-C-IV) ovarian, primary peritoneal and fallopian tube cancer. International Journal of Gynecological Cancer. 32. A347–A348.

Nero, Camilla, Elena Giudice, Vanda Salutari, et al.. (2022). Advanced and recurrent endometrial cancer: State of the art and future perspectives. Critical Reviews in Oncology/Hematology. 180. 103851–103851. 36 indexed citations

Musacchio, Lucia, Vanda Salutari, Floriana Camarda, et al.. (2022). Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives. Frontiers in Oncology. 12. 831612–831612. 4 indexed citations

Scambia, Giovanni, Lucia Musacchio, Salvatore Siena, et al.. (2022). 45TiP A randomized, molecular driven phase II trial of carboplatin-paclitaxel-bev vs carboplatin-paclitaxel-bev-rucaparib vs carboplatin-paclitaxel-rucaparib, selected according to HRD status, in patients with advanced ovarian cancer. Annals of Oncology. 33. S401–S401. 1 indexed citations

Musacchio, Lucia, Floriana Camarda, Viola Ghizzoni, et al.. (2022). Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?. ESMO Open. 7(4). 100536–100536. 27 indexed citations

10.

Giudice, Elena, Vanda Salutari, Caterina Ricci, et al.. (2021). Gut microbiota and its influence on ovarian cancer carcinogenesis, anticancer therapy and surgical treatment: A literature review. Critical Reviews in Oncology/Hematology. 168. 103542–103542. 8 indexed citations

11.

Musacchio, Lucia, Vanda Salutari, Sandro Pignata, et al.. (2021). Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33). International Journal of Gynecological Cancer. 31(10). 1369–1373. 21 indexed citations

12.

Giudice, Elena, Floriana Camarda, Vanda Salutari, et al.. (2021). Tisotumab Vedotin in Cervical Cancer: Current Status and Future Perspectives. 17(2). 68–68. 3 indexed citations

13.

Cappuccio, Serena, et al.. (2020). Trametinib response in heavily pretreated high-grade ovarian cancer: One step towards precision medicine. Gynecologic Oncology Reports. 32. 100547–100547. 6 indexed citations

14.

Corrado, Giacomo, Eleonora Palluzzi, Carolina Bottoni, et al.. (2019). New medical approaches in advanced ovarian cancer. Minerva Medica. 110(4). 367–384. 5 indexed citations

15.

Fanfani, Francesco, Giorgia Monterossi, Viola Ghizzoni, et al.. (2018). One-Step Nucleic Acid Amplification (OSNA): A fast molecular test based on CK19 mRNA concentration for assessment of lymph-nodes metastases in early stage endometrial cancer. PLoS ONE. 13(4). e0195877–e0195877. 32 indexed citations

16.

Ghizzoni, Viola, et al.. (2018). Spontaneous Resolution of an Acquired Uterine Arteriovenous Malformation in an Elderly Primigravida. American Journal of Case Reports. 19. 1140–1145. 5 indexed citations

17.

Sozzi, Giulio, Roberto Berretta, T. Frusca, et al.. (2018). Tumor Size, an Additional Risk Factor of Local Recurrence in Low-Risk Endometrial Cancer. International Journal of Gynecological Cancer. 28(4). 684–691. 25 indexed citations

18.

Sorbi, Flavia, Gianna Baroni, Serena Pillozzi, et al.. (2018). Luteinizing Hormone/Human Chorionic Gonadotropin Receptor Immunohistochemical Score Associated with Poor Prognosis in Endometrial Cancer Patients. BioMed Research International. 2018. 1–6. 6 indexed citations

19.

Sorbi, Flavia, Ivo Noci, Viola Ghizzoni, et al.. (2016). New adverse obstetrics outcomes associated with endometriosis: a retrospective cohort study. Archives of Gynecology and Obstetrics. 295(1). 141–151. 39 indexed citations

20.

Noci, Ivo, Flavia Sorbi, Serena Pillozzi, et al.. (2016). LH/hCG-Receptor Expression May Have a Negative Prognostic Value in Low-Risk Endometrial Cancer. Frontiers in Oncology. 6. 190–190. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact